ISRCTN34662787已完成1 期
Phase 1 trial HMR code: 22-006 The full scientific title will be published within 30 months after the end of the trial
Heptares Therapeutics (United Kingdom)0 个研究点目标入组 16 人开始时间: 2022年7月25日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Healthy human volunteer
排除标准
- •The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
研究者
相似试验
进行中（未招募）
1 期
Phase I trial HMR code: 23-006ISRCTN23220202Gedeon Richter (Hungary)168
进行中（未招募）
1 期
Phase 1 trial HMR code: 22-017Healthy volunteersISRCTN51803225eurocrine Biosciences (United States)134
进行中（未招募）
1 期
Phase 1 trial, HMR code: 21-004The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record when the results are published, which will be within 30 months after the trial has ended.Not SpecifiedISRCTN12926361Gedeon Richter Plc104
进行中（未招募）
1 期
Phase I trial, HMR code: 22-016Healthy volunteersISRCTN17231793xera Pharma UK Ltd104
进行中（未招募）
1 期
Phase 1 trial HMR code: 23-011Healthy volunteersISRCTN17328380Asceneuron (Switzerland)16